{"count":10,"index":{"built_at":"2026-07-27T16:16:05.694753+00:00","public_records":55311,"revision":"e158e97e92061becca471d86"},"query":{"area":null,"kind":null,"lang":null,"limit":10,"match_mode":"all_terms","q":"Evidence check: LDL in the context of menopause"},"results":[{"answer":"During menopause, declining estrogen levels shift the lipid profile: LDL cholesterol typically rises, while HDL often remains stable or slightly decreases. This increase is a normal physiological change but elevates cardiovascular risk. Direct, evidence-based links between specific genetic variants (e.g., APOE, PCSK9) and LDL rise in menopause are weak. Most studies are observational with moderate effect sizes. Consumer tests like MyBody-X may offer SNP-based risk scores, but these are not sufficiently validated for predicting menopause-related LDL changes. Clinically, regular lipid monitoring, lifestyle modifications (diet, exercise), and possibly hormone therapy or statins are more relevant. The evidence for genetic testing in this context is 'human-moderate' to 'mixed'. Caveat: Elevated LDL in menopause warrants medical evaluation, not solely genetic interpretation.","area":"gesundheit","canonical_id":"gesundheit:canonical-bdb46bc43c80fbef6a135acd","id":"public-9700ed074a2a1b3a2a1371cf","kind":"qa","language":"en","publication_status":"existing_native_answer_privacy_screened_sources_pending","question":"Evidence check: LDL in the context of menopause","score":21.51964429,"snippet":"During menopause, declining estrogen levels shift the lipid profile: LDL cholesterol typically rises, while HDL often remains stable or slightly decreases. This increase is a normal physiological change but elevates cardiovascular risk. Direct, evidence-based links between specific genetic variants (e.g., APOE, PCSK9) and LDL rise in menopause are weak. Most studies are observational with moderate effect sizes. Consumer tests like MyBody-X may offer SNP-based risk scores, but these are not sufficiently validated for predicting menopause-related LDL changes. Clinically, regular lipid monitoring, lifestyle modifications (diet, exercise), and possibly hormone therapy or statins are more relevan","sources":[],"title":"Evidence check: LDL in the context of menopause","url":"https://tikki.wiki/wissen/gesundheit/frage/public-9700ed074a2a1b3a2a1371cf/evidence-check-ldl-in-the-context-of-menopause/","verification":{"claim_support_verified":false,"human_reviewed":false,"quote_exact_match":false,"source_identity_verified":false,"tier":"existing_native_answer_privacy_screened_sources_pending"}},{"answer":"ApoB (apolipoprotein B) is the primary structural protein of atherogenic lipoproteins (LDL, VLDL, IDL) and is considered a more accurate marker of cardiovascular risk than LDL cholesterol alone. During menopause, cardiovascular risk rises sharply due to estrogen decline – estrogen enhances LDL clearance and inhibits lipid oxidation. Studies indicate that postmenopausal women have higher ApoB levels compared to premenopausal women, independent of total cholesterol. Menopause also shifts LDL toward smaller, denser particles, which are more atherogenic and better captured by ApoB. However, the evidence base is not fully robust: no large randomized trials have specifically tested ApoB-lowering interventions in menopause. Most data come from observational studies and post-hoc analyses. Clinical guidelines (e.g., ESC/EAS) recommend ApoB as a secondary target, especially in women with metabolic syndrome or diabetes. In practice, measuring ApoB in menopausal women with elevated risk (e.g., early menopause, family history) can refine treatment decisions. Caveat: ApoB alone does not replace a full lipid panel (LDL, HDL, triglycerides) and should be interpreted alongside lifestyle, inflammatory markers (hsCRP), and hormonal status. Evidence is moderate – mechanistically sound but not confirmed by menopause-specific intervention trials.","area":"gesundheit","canonical_id":"gesundheit:canonical-56686c1136b2965adaf69603","id":"public-4fab64063a5c818ba35aab6f","kind":"qa","language":"en","publication_status":"existing_native_answer_privacy_screened_sources_pending","question":"Evidence check: ApoB in the context of menopause","score":21.09445496,"snippet":"ApoB (apolipoprotein B) is the primary structural protein of atherogenic lipoproteins (LDL, VLDL, IDL) and is considered a more accurate marker of cardiovascular risk than LDL cholesterol alone. During menopause, cardiovascular risk rises sharply due to estrogen decline – estrogen enhances LDL clearance and inhibits lipid oxidation. Studies indicate that postmenopausal women have higher ApoB levels compared to premenopausal women, independent of total cholesterol. Menopause also shifts LDL toward smaller, denser particles, which are more atherogenic and better captured by ApoB. However, the evidence base is not fully robust: no large randomized trials have specifically tested ApoB-lowering i","sources":[],"title":"Evidence check: ApoB in the context of menopause","url":"https://tikki.wiki/wissen/gesundheit/frage/public-4fab64063a5c818ba35aab6f/evidence-check-apob-in-the-context-of-menopause/","verification":{"claim_support_verified":false,"human_reviewed":false,"quote_exact_match":false,"source_identity_verified":false,"tier":"existing_native_answer_privacy_screened_sources_pending"}},{"answer":"The link between LDL cholesterol and menopause is well-established: declining estrogen levels typically raise LDL, increasing cardiovascular risk. Evidence is human-strong (epidemiological and physiological studies). However, consumer DNA tests (e.g., MyBody-X) cannot reliably predict this rise – they provide only weak polygenic hints. A blood lipid panel is far more informative for individual risk assessment. Caveat: Menopause is a natural transition, but elevated LDL should be monitored by a physician, especially with other risk factors. Evidence for nutrigenetic tests in this context is marketing-based and not clinically validated.","area":"gesundheit","canonical_id":"gesundheit:canonical-da46c57024aabef57a6c1318","id":"public-bfaee874fdb877726ac70b1e","kind":"qa","language":"en","publication_status":"existing_native_answer_privacy_screened_sources_pending","question":"Evidence check: LDL in the context of Wechseljahre","score":21.09280704,"snippet":"The link between LDL cholesterol and menopause is well-established: declining estrogen levels typically raise LDL, increasing cardiovascular risk. Evidence is human-strong (epidemiological and physiological studies). However, consumer DNA tests (e.g., MyBody-X) cannot reliably predict this rise – they provide only weak polygenic hints. A blood lipid panel is far more informative for individual risk assessment. Caveat: Menopause is a natural transition, but elevated LDL should be monitored by a physician, especially with other risk factors. Evidence for nutrigenetic tests in this context is marketing-based and not clinically validated.","sources":[],"title":"Evidence check: LDL in the context of Wechseljahre","url":"https://tikki.wiki/wissen/gesundheit/frage/public-bfaee874fdb877726ac70b1e/evidence-check-ldl-in-the-context-of-wechseljahre/","verification":{"claim_support_verified":false,"human_reviewed":false,"quote_exact_match":false,"source_identity_verified":false,"tier":"existing_native_answer_privacy_screened_sources_pending"}},{"answer":"ApoB (apolipoprotein B) is a direct measure of the number of atherogenic particles (LDL, VLDL) in the blood and is considered a stronger predictor of cardiovascular risk than LDL cholesterol alone. During menopause, estrogen decline leads to increased LDL and ApoB levels, along with a shift toward smaller, denser LDL particles – a particularly atherogenic profile. The evidence for ApoB as a risk marker in menopause is solid (prospective cohorts, meta-analyses). However, randomized trials specifically targeting ApoB in postmenopausal women are lacking. Current guidelines (ESC, AHA) recommend ApoB as an alternative or complementary marker, especially in women with metabolic syndrome or diabetes. An ApoB target < 80 mg/dL (or < 65 mg/dL for high risk) is often suggested. MyBody-X tests can measure ApoB, but interpretation requires clinical context. Caveat: No home test replaces a physician's risk assessment. Evidence: human-moderate (strong association, but no RCTs for menopause-specific cutoffs).","area":"gesundheit","canonical_id":"gesundheit:canonical-7dfcad29b2db1f026e1efda9","id":"public-03f01f467a517f852cc05e3f","kind":"qa","language":"en","publication_status":"existing_native_answer_privacy_screened_sources_pending","question":"Evidence check: ApoB in the context of Wechseljahre","score":20.709732,"snippet":"ApoB (apolipoprotein B) is a direct measure of the number of atherogenic particles (LDL, VLDL) in the blood and is considered a stronger predictor of cardiovascular risk than LDL cholesterol alone. During menopause, estrogen decline leads to increased LDL and ApoB levels, along with a shift toward smaller, denser LDL particles – a particularly atherogenic profile. The evidence for ApoB as a risk marker in menopause is solid (prospective cohorts, meta-analyses). However, randomized trials specifically targeting ApoB in postmenopausal women are lacking. Current guidelines (ESC, AHA) recommend ApoB as an alternative or complementary marker, especially in women with metabolic syndrome or diabete","sources":[],"title":"Evidence check: ApoB in the context of Wechseljahre","url":"https://tikki.wiki/wissen/gesundheit/frage/public-03f01f467a517f852cc05e3f/evidence-check-apob-in-the-context-of-wechseljahre/","verification":{"claim_support_verified":false,"human_reviewed":false,"quote_exact_match":false,"source_identity_verified":false,"tier":"existing_native_answer_privacy_screened_sources_pending"}},{"answer":"HDL cholesterol levels often shift during menopause: estrogen decline can lower HDL or alter subclass distribution (less large, protective HDL2). However, the HDL-raising hypothesis has been largely refuted by CETP inhibitor trials and Mendelian randomization – HDL is a risk marker, not a causal protective factor. More relevant are HDL functionality (cholesterol efflux capacity) and the full lipid panel (LDL, triglycerides, Lp(a)). The 2025 ESC/EAS guidelines emphasize LDL reduction and universal Lp(a) screening, not HDL elevation. For menopausal women, this means: HDL in the normal range is fine, but isolated HDL boosting via lifestyle (e.g., alcohol, estrogen) is not cardioprotective. Focus should be on overall lipid profile, blood pressure, glucose, and lifestyle (exercise, Mediterranean diet). Evidence: human-moderate (observational studies, no RCTs for HDL raising).","area":"gesundheit","canonical_id":"gesundheit:canonical-825e46b6ec9d3001fc982346","id":"public-50dbe77e94fd9cc230f16d6b","kind":"qa","language":"en","publication_status":"existing_native_answer_privacy_screened_sources_pending","question":"Evidence check: HDL in the context of menopause","score":20.58393787,"snippet":"HDL cholesterol levels often shift during menopause: estrogen decline can lower HDL or alter subclass distribution (less large, protective HDL2). However, the HDL-raising hypothesis has been largely refuted by CETP inhibitor trials and Mendelian randomization – HDL is a risk marker, not a causal protective factor. More relevant are HDL functionality (cholesterol efflux capacity) and the full lipid panel (LDL, triglycerides, Lp(a)). The 2025 ESC/EAS guidelines emphasize LDL reduction and universal Lp(a) screening, not HDL elevation. For menopausal women, this means: HDL in the normal range is fine, but isolated HDL boosting via lifestyle (e.g., alcohol, estrogen) is not cardioprotective. Focu","sources":[],"title":"Evidence check: HDL in the context of menopause","url":"https://tikki.wiki/wissen/gesundheit/frage/public-50dbe77e94fd9cc230f16d6b/evidence-check-hdl-in-the-context-of-menopause/","verification":{"claim_support_verified":false,"human_reviewed":false,"quote_exact_match":false,"source_identity_verified":false,"tier":"existing_native_answer_privacy_screened_sources_pending"}},{"answer":"The provided contexts contain no specific information on triglycerides in the context of menopause. Generally, it is known that the decline in estrogen during menopause shifts the lipid profile: LDL cholesterol and triglycerides often rise, while HDL cholesterol tends to decrease. This increases cardiovascular risk. Triglycerides are an important biomarker, modifiable by diet, exercise, and possibly hormone therapy. However, this statement is based on general medical knowledge, not on the given sources. Therefore, the evidence grade is 'unclear'. A triglyceride test during menopause can be useful but must be interpreted by a physician. Caveat: home tests provide only a snapshot and do not replace clinical diagnostics. If elevated, lifestyle changes and medical follow-up are recommended.","area":"gesundheit","canonical_id":"gesundheit:canonical-f9cd387fe16eeb879b152936","id":"public-16b49a797bc24bd8acab9e47","kind":"qa","language":"en","publication_status":"existing_native_answer_privacy_screened_sources_pending","question":"Evidence check: Triglyceride in the context of menopause","score":19.99461861,"snippet":"The provided contexts contain no specific information on triglycerides in the context of menopause. Generally, it is known that the decline in estrogen during menopause shifts the lipid profile: LDL cholesterol and triglycerides often rise, while HDL cholesterol tends to decrease. This increases cardiovascular risk. Triglycerides are an important biomarker, modifiable by diet, exercise, and possibly hormone therapy. However, this statement is based on general medical knowledge, not on the given sources. Therefore, the evidence grade is 'unclear'. A triglyceride test during menopause can be useful but must be interpreted by a physician. Caveat: home tests provide only a snapshot and do not re","sources":[],"title":"Evidence check: Triglyceride in the context of menopause","url":"https://tikki.wiki/wissen/gesundheit/frage/public-16b49a797bc24bd8acab9e47/evidence-check-triglyceride-in-the-context-of-menopause/","verification":{"claim_support_verified":false,"human_reviewed":false,"quote_exact_match":false,"source_identity_verified":false,"tier":"existing_native_answer_privacy_screened_sources_pending"}},{"answer":"Lowering triglycerides during menopause is clinically relevant because estrogen decline often raises triglycerides and LDL cholesterol. The provided context lacks specific studies or guidelines on this topic. General recommendations include a Mediterranean diet, omega-3 fatty acids (e.g., from fish or flaxseed), regular exercise, and weight management. MyBody-X offers metabolic, DNA, and nutrient tests that may indicate individual risk factors – for example, genetic variants in lipid metabolism (e.g., APOA5, LPL) or inflammatory markers. However, the evidence for directly reducing triglycerides through such tests is weak to moderate; they provide orientation rather than clinical diagnosis. Important: For significantly elevated levels or additional risk factors (e.g., diabetes), medical evaluation is necessary. Hormone replacement therapy can affect triglycerides – this should be discussed with a physician. Evidence grade: mixed/unclear, as the context does not provide specific supporting data.","area":"gesundheit","canonical_id":"gesundheit:canonical-102bfaa1bd68dcb5214ccb45","id":"public-88fe9e129f566bb5c458527f","kind":"qa","language":"en","publication_status":"existing_native_answer_privacy_screened_sources_pending","question":"Evidence check: Triglyceride senken in the context of menopause","score":19.80661211,"snippet":"Lowering triglycerides during menopause is clinically relevant because estrogen decline often raises triglycerides and LDL cholesterol. The provided context lacks specific studies or guidelines on this topic. General recommendations include a Mediterranean diet, omega-3 fatty acids (e.g., from fish or flaxseed), regular exercise, and weight management. MyBody-X offers metabolic, DNA, and nutrient tests that may indicate individual risk factors – for example, genetic variants in lipid metabolism (e.g., APOA5, LPL) or inflammatory markers. However, the evidence for directly reducing triglycerides through such tests is weak to moderate; they provide orientation rather than clinical diagnosis. I","sources":[],"title":"Evidence check: Triglyceride senken in the context of menopause","url":"https://tikki.wiki/wissen/gesundheit/frage/public-88fe9e129f566bb5c458527f/evidence-check-triglyceride-senken-in-the-context-of-menopause/","verification":{"claim_support_verified":false,"human_reviewed":false,"quote_exact_match":false,"source_identity_verified":false,"tier":"existing_native_answer_privacy_screened_sources_pending"}},{"answer":"The usefulness of a Cardio Risk Check (cardiovascular risk test) during menopause cannot be fully assessed from the provided context. The context mentions general cardiovascular biomarkers such as LDL, ApoB, Lp(a), CRP, and homocysteine, which are supported by a systematic review for reflecting cardiovascular risk. Menopause increases cardiovascular risk due to hormonal changes (declining estrogen), so such a test could theoretically be beneficial. However, the context emphasizes that single biomarkers are insufficient and results must be interpreted by a doctor. No specific studies on menopause are cited. The test is a consumer product; marketing claims should be separated from evidence. Without direct data on menopause, the utility remains uncertain. Recommendation: consult a physician who can consider individual risk factors.","area":"gesundheit","canonical_id":"gesundheit:canonical-f2be0b6e206cc9cd0f25dd99","id":"public-c1fa0046b64a2363d24925b1","kind":"qa","language":"en","publication_status":"existing_native_answer_privacy_screened_sources_pending","question":"Is Cardio Risk Check | Herz-Kreislauf Risiko-Test useful for menopause?","score":19.59980999,"snippet":"The usefulness of a Cardio Risk Check (cardiovascular risk test) during menopause cannot be fully assessed from the provided context. The context mentions general cardiovascular biomarkers such as LDL, ApoB, Lp(a), CRP, and homocysteine, which are supported by a systematic review for reflecting cardiovascular risk. Menopause increases cardiovascular risk due to hormonal changes (declining estrogen), so such a test could theoretically be beneficial. However, the context emphasizes that single biomarkers are insufficient and results must be interpreted by a doctor. No specific studies on menopause are cited. The test is a consumer product; marketing claims should be separated from evidence. Wi","sources":[],"title":"Is Cardio Risk Check | Herz-Kreislauf Risiko-Test useful for menopause?","url":"https://tikki.wiki/wissen/gesundheit/frage/public-c1fa0046b64a2363d24925b1/is-cardio-risk-check-herz-kreislauf-risiko-test-useful-for-menopause/","verification":{"claim_support_verified":false,"human_reviewed":false,"quote_exact_match":false,"source_identity_verified":false,"tier":"existing_native_answer_privacy_screened_sources_pending"}},{"answer":"Menopause (Wechseljahre) involves hormonal shifts that can alter lipid profiles. HDL cholesterol ('good' cholesterol) shows a nuanced pattern: during perimenopause HDL may initially rise, but later it can decline or shift toward less protective subtypes (smaller HDL particles). Evidence is based on observational studies and is rated 'human-moderate' – no large RCTs prove a causal menopause effect on HDL. Caveat: isolated low HDL is not a standalone risk factor; it must be interpreted alongside LDL, triglycerides, and overall cardiovascular risk. Lifestyle interventions (exercise, Mediterranean diet, smoking cessation) remain the most evidence-supported ways to support HDL. Hormone therapy may raise HDL but its clinical benefit is debated. The provided context lacks direct data on HDL and menopause; this answer relies on general medical knowledge. Consumers should not over-focus on a single biomarker – a comprehensive health check including blood pressure, glucose, and inflammation markers is more informative.","area":"gesundheit","canonical_id":"gesundheit:canonical-8a1d96215378bf1d195e0af8","id":"public-3fd14b1cbabd6d5fe86f0d7b","kind":"qa","language":"en","publication_status":"existing_native_answer_privacy_screened_sources_pending","question":"Evidence check: HDL in the context of Wechseljahre","score":19.44646896,"snippet":"Menopause (Wechseljahre) involves hormonal shifts that can alter lipid profiles. HDL cholesterol ('good' cholesterol) shows a nuanced pattern: during perimenopause HDL may initially rise, but later it can decline or shift toward less protective subtypes (smaller HDL particles). Evidence is based on observational studies and is rated 'human-moderate' – no large RCTs prove a causal menopause effect on HDL. Caveat: isolated low HDL is not a standalone risk factor; it must be interpreted alongside LDL, triglycerides, and overall cardiovascular risk. Lifestyle interventions (exercise, Mediterranean diet, smoking cessation) remain the most evidence-supported ways to support HDL. Hormone therapy ma","sources":[],"title":"Evidence check: HDL in the context of Wechseljahre","url":"https://tikki.wiki/wissen/gesundheit/frage/public-3fd14b1cbabd6d5fe86f0d7b/evidence-check-hdl-in-the-context-of-wechseljahre/","verification":{"claim_support_verified":false,"human_reviewed":false,"quote_exact_match":false,"source_identity_verified":false,"tier":"existing_native_answer_privacy_screened_sources_pending"}},{"answer":"Whether a 'Cardio Risk Check' is useful during menopause depends on what exactly is measured. Menopause increases cardiovascular risk due to declining estrogen, affecting LDL cholesterol, blood pressure, and inflammatory markers. A test covering these classic risk factors may provide some insight, but it cannot replace clinical risk stratification (e.g., SCORE2). The provided context lacks specific studies or product details on a Cardio Risk Check for menopause. Moreover, the context repeatedly warns that consumer DNA tests often miss clinically relevant genes (e.g., CYP2D6, VKORC1) and are not validated for medication dosing. Without menopause-specific validation, the utility of such a check remains unclear. An evidence-based risk assessment should always involve a physician who considers hormonal status, lifestyle, and family history. Therefore, be cautious of overblown claims – the test may offer a rough indication but is no substitute for a clinical evaluation.","area":"gesundheit","canonical_id":"gesundheit:canonical-a7a2a7ad2bca96e9761e0e46","id":"public-a58b147afb05c4a8021b422b","kind":"qa","language":"en","publication_status":"existing_native_answer_privacy_screened_sources_pending","question":"Is Cardio Risk Check useful for menopause?","score":19.31659847,"snippet":"Whether a 'Cardio Risk Check' is useful during menopause depends on what exactly is measured. Menopause increases cardiovascular risk due to declining estrogen, affecting LDL cholesterol, blood pressure, and inflammatory markers. A test covering these classic risk factors may provide some insight, but it cannot replace clinical risk stratification (e.g., SCORE2). The provided context lacks specific studies or product details on a Cardio Risk Check for menopause. Moreover, the context repeatedly warns that consumer DNA tests often miss clinically relevant genes (e.g., CYP2D6, VKORC1) and are not validated for medication dosing. Without menopause-specific validation, the utility of such a chec","sources":[],"title":"Is Cardio Risk Check useful for menopause?","url":"https://tikki.wiki/wissen/gesundheit/frage/public-a58b147afb05c4a8021b422b/is-cardio-risk-check-useful-for-menopause/","verification":{"claim_support_verified":false,"human_reviewed":false,"quote_exact_match":false,"source_identity_verified":false,"tier":"existing_native_answer_privacy_screened_sources_pending"}}],"schema_version":"tikki.search-response.v1"}